LabCorp launches Qiagen's FGFR test for bladder cancer

By staff writers

May 10, 2019 -- LabCorp announced on May 10 that it has begun offering Qiagen's therascreen companion diagnostic for detecting FGFR mutations in bladder cancer.

The FGFR Rotor-Gene Q (RGQ) reverse transcription polymerase chain reaction (RT-PCR) kit is the first product introduced through LabCorp's participation with Qiagen in a lab readiness program aimed at making new companion diagnostics available for drugs soon after approval by the U.S. Food and Drug Administration (FDA).

The agency approved the diagnostic on April 12 for use in screening for FGFR2 and FGFR3 mutations in locally advanced or metastatic bladder cancer that has progressed after treatment with platinum-based chemotherapy in conjunction with the targeted drug erdafitinib (Balversa, Johnson & Johnson). The drug's labeling specifies that patients should be selected for treatment using an FDA-approved companion diagnostic.

LabCorp to exchange research units with Envigo
LabCorp and Envigo have announced a deal in which LabCorp will buy Envigo's nonclinical contract research services business, while Envigo will absorb...

Copyright © 2019

Last Updated np 2/3/2020 4:41:28 PM

Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.